High Free Cash Flow Stocks
INCY is currently part of our High Free Cash Flow Stocks screen, indicating it generates strong cash flows relative to its price.
INCYTE CORP (INCY) Stock Price & Overview
NASDAQ:INCY • US45337C1027
Current stock price
95.93 USD
+1.63 (+1.73%)
At close:
95 USD
-0.93 (-0.97%)
After Hours:
The current stock price of INCY is 95.93 USD. Today INCY is up by 1.73%. In the past month the price decreased by -1.44%. In the past year, price increased by 58.35%.
INCY Key Statistics
52-Week Range53.56 - 112.29
Current INCY stock price positioned within its 52-week range.
1-Month Range89.25 - 97.8599
Current INCY stock price positioned within its 1-month range.
- Market Cap
- 19.091B
- P/E
- 14.13
- Fwd P/E
- 12.53
- EPS (TTM)
- 6.79
- Dividend Yield
- N/A
INCY Stock Performance
Today
+1.73%
1 Week
+3.98%
1 Month
-1.44%
3 Months
-5.41%
Longer-term
6 Months +10.45%
1 Year +58.35%
2 Years +84.30%
3 Years +28.92%
5 Years +12.36%
10 Years +32.74%
INCY Stock Chart
INCY Stock Screens
INCY currently appears in the following ChartMill screener lists.
Fastest Growing Stocks
INCY is part of our fastest growing stocks screen, indicating it has high EPS and sales growth.
INCY Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to INCY. When comparing the yearly performance of all stocks, INCY is one of the better performing stocks in the market, outperforming 80.55% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
INCY Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to INCY. INCY gets an excellent profitability rating and is at the same time showing great financial health properties.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
INCY Earnings
On February 10, 2026 INCY reported an EPS of 1.8 and a revenue of 1.51B. The company missed EPS expectations (-8.46% surprise) and beat revenue expectations (9.27% surprise).
Next Earnings DateApr 27, 2026
Last Earnings DateFeb 10, 2026
PeriodQ4 / 2025
EPS Reported$1.80
Revenue Reported1.507B
EPS Surprise -8.46%
Revenue Surprise 9.27%
INCY Forecast & Estimates
33 analysts have analysed INCY and the average price target is 109.83 USD. This implies a price increase of 14.49% is expected in the next year compared to the current price of 95.93.
For the next year, analysts expect an EPS growth of 12.8% and a revenue growth 12.41% for INCY
Analysts
Analysts75.15
Price Target109.83 (14.49%)
EPS Next Y12.8%
Revenue Next Year12.41%
INCY Groups
Sector & Classification
Sector
Health Care Sub-Industry
Biotechnology INCY Financial Highlights
Over the last trailing twelve months INCY reported a non-GAAP Earnings per Share(EPS) of 6.79. The EPS increased by 414.39% compared to the year before.
Income Statements
Revenue(TTM)5.14B
Net Income(TTM)1.29B
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 25.03% | ||
| ROA | 18.49% | ||
| ROE | 24.9% | ||
| Debt/Equity | 0.01 |
Chartmill High Growth Momentum
EPS Q2Q%25.87%
Sales Q2Q%27.84%
EPS 1Y (TTM)414.39%
Revenue 1Y (TTM)21.22%
INCY Ownership
Ownership
Inst Owners104.37%
Shares199.01M
Float194.97M
Ins Owners0.94%
Short Float %5.66%
Short Ratio6.17
INCY Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 380.121B | ||
| AMGN | AMGEN INC | 15.24 | 190.443B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 174.171B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 113.617B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 82.171B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 43.596B | ||
| INSM | INSMED INC | N/A | 35.536B | ||
| NTRA | NATERA INC | N/A | 28.801B | ||
| BIIB | BIOGEN INC | 11.03 | 26.972B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.995B | ||
| MRNA | MODERNA INC | N/A | 19.759B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.548B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About INCY
Company Profile
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. The company is headquartered in Wilmington, Delaware and currently employs 2,844 full-time employees. The firm operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The firm's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
Company Info
IPO: 1993-12-06
INCYTE CORP
1801 Augustine Cut-Off
Wilmington DELAWARE 19803 US
CEO: Herve Hoppenot
Employees: 2617
Phone: 13026365400
INCYTE CORP / INCY FAQ
What does INCY do?
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. The company is headquartered in Wilmington, Delaware and currently employs 2,844 full-time employees. The firm operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The firm's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
What is the stock price of INCYTE CORP today?
The current stock price of INCY is 95.93 USD. The price increased by 1.73% in the last trading session.
What is the dividend status of INCYTE CORP?
INCY does not pay a dividend.
What is the ChartMill rating of INCYTE CORP stock?
INCY has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
Can you provide the sector and industry classification for INCYTE CORP?
INCYTE CORP (INCY) operates in the Health Care sector and the Biotechnology industry.
What is the market capitalization of INCY stock?
INCYTE CORP (INCY) has a market capitalization of 19.09B USD. This makes INCY a Large Cap stock.
What is the Short Interest ratio of INCYTE CORP (INCY) stock?
The outstanding short interest for INCYTE CORP (INCY) is 5.66% of its float.